Literature DB >> 8927510

Interleukin 1 beta and phorbol ester induce tumour necrosis factor alpha production in a hepatic cell line (HepG2).

S Frede1, J Fandrey, W Jelkmann.   

Abstract

Tumour necrosis factor "alpha" (TNF "alpha") is a pleiotropic cytokine that is produced mainly by monocytes and macrophages. TNF "alpha" appears to be responsible for many of the inflammatory and necrotic changes seen in malignant or infectious liver diseases. In addition, blood levels of TNF "alpha" have been reported to be elevated in those with hepatic diseases. Although TNF "alpha" is synthesized mainly by monocytes and macrophages, its production has recently been found in nonhaemopoietic cells as well. Therefore we have used the human liver cell line HepG2 to test for the inducible production of TNF "alpha" in hepatic parenchymal cells. No constitutive TNF "alpha" gene expression was detected by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). However, treatment with the proinflammatory cytokine interleukin 1 "beta" (IL-1 "beta") or phorbol 12-myristate-acetate (PMA) led to a marked increase in TNF "alpha" mRNA levels. Maximal TNF "alpha" mRNA levels were observed after 3-h incubation periods, decreased thereafter and became undetectable after 12 h. The culture supernatant from cells treated with IL-1 "beta" or PMA contained significant amounts of TNF "alpha" protein which was immunologically detectable and biologically active. We believe that our report of inducible TNF "alpha" production in this widely available hepatic cell line adds a valuable tool for understanding TNF "alpha" gene expression in nonhaematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8927510     DOI: 10.1007/s004240050086

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  22 in total

1.  Competitive PCR.

Authors:  P D Siebert; J W Larrick
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

2.  Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2.

Authors:  J H Kelly; G J Darlington
Journal:  In Vitro Cell Dev Biol       Date:  1989-02

3.  Tumor necrosis factor-alpha induces a kappa B sequence-specific DNA-binding protein in human hepatoblastoma HepG2 cells.

Authors:  R Banerjee; S Karpen; M Siekevitz; G Lengyel; J Bauer; G Acs
Journal:  Hepatology       Date:  1989-12       Impact factor: 17.425

Review 4.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.

Authors:  K J Tracey; A Cerami
Journal:  Annu Rev Med       Date:  1994       Impact factor: 13.739

5.  Immunocytochemical demonstration of erythropoietin in hypoxic human hepatoma cultures.

Authors:  C Herkens; M Wolff; J Fandrey; F Schuler; W Jelkmann
Journal:  Histochemistry       Date:  1993-10

6.  Role of protein kinase C activity in tumor necrosis factor-alpha gene expression. Involvement at the transcriptional level.

Authors:  I Y Chung; J Kwon; E N Benveniste
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

7.  Serum-free in vitro bioassay for the detection of tumor necrosis factor.

Authors:  S M Kramer; M E Carver
Journal:  J Immunol Methods       Date:  1986-11-06       Impact factor: 2.303

8.  Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light.

Authors:  A Köck; T Schwarz; R Kirnbauer; A Urbanski; P Perry; J C Ansel; T A Luger
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

9.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

Authors:  K J Tracey; H Wei; K R Manogue; Y Fong; D G Hesse; H T Nguyen; G C Kuo; B Beutler; R S Cotran; A Cerami
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor.

Authors:  M Meyer; R Schreck; P A Baeuerle
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.